Satori Capital
VC Fund
Dallas, United States
Satori Capital is a team of passionate CEOs, investment professionals, and sustainability leaders on a mission to invest in aligned private companies and help them grow - this is our life's work. We assemble the partners, resources, tools, and frameworks to help inspired leaders achieve their vision and continue building their business.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 32%
Last updated:
For AI agents: llms.txt
Industries Satori Capital invests in
Stages Satori Capital invests in
Countries Satori Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chad Cook
|
|||
Claire McInnis
|
|||
John Grafer
|
Investment Focus
Industry
- Health Care 12 (43%)
- Medical 6 (21%)
- E-Commerce 3 (11%)
- Biotechnology 3 (11%)
- Software 2 (7%)
Stage
- Series A 8 (29%)
- Seed 7 (25%)
- Funding Round 4 (14%)
- Private Equity 3 (11%)
- Angel 2 (7%)
Country
- United States 20 (71%)
- China 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christiana Wyly
Operating Partner
|
Operating Partner | Total investments: 3 | Find email | |
|
Chad Cook
Director - Business Development
|
Director - Business Development | Total investments: 0 | Find email | |
|
Claire McInnis
Vice President of Finance
|
Vice President of Finance | Total investments: 0 | Find email | |
Craig Lentzsch
Operating Partner
|
Operating Partner | Total investments: 2 | Find email | |
|
John Grafer
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gilgamesh Pharmaceuticals
|
Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $60M / Series A / Mar 24, 2026 | |
NextSense
|
NextSense unlocks brain health with real-world data insights and practical, scientific wisdom for daily living. It aims to catalyze brain health in science and culture. The company was founded in 2020 and is headquartered in Mountain View, California. | $16.3M / Series A / Nov 11, 2025 | |
Ampa Health
|
Ampa Health is a health technology business developing scalable brain stimulation technologies to treat depression, anxiety, and addiction. | $8.5M / Seed / Oct 22, 2025 | |
Holobiome
|
Holobiome is an owner and operator of a therapeutic company intended to treat diseases of the enteric and central nervous systems. The company's platform delivers microbiome-based therapeutics to patients and the marketplace by treating depression, anxiety, and other mental health problems including our metabolism and the immune response,enabling patients to recover quickly from their diseases easily without any pain and suffering.Holobiome was established in 2015 and is based in Cambridge, Massachusetts. | $9M / Seed / Oct 09, 2024 | |
Hoodie Analytics
|
Hoodie Analytics was founded on the belief that cannabis businesses need deeper, operational insights to better compete. Our team has decades of experience in cannabis as well as e-commerce intelligence & market measurement in markets like CPG & FMCG.With Hoodie Analytics, you get an indispensable partner tracking the movements of themarket. You get access to the best people, processes, and data which deliver an unfair advantage over the the competition. You can focus on running your business. We’ll deliver the insights needed to outgrow the pack. | $5M / Series A / Jun 27, 2024 | |
Automatic Fire Protection
|
Automatic Fire Protection, Inc. is a construction firm dealing in fire protection system design, installation, and maintenance. | May 30, 2024 | |
|
Automatic Fire Protection
|
Automatic Fire Protection, Inc. is a construction firm dealing in fire protection system design, installation, and maintenance. | Private Equity / May 30, 2024 | |
Feel Therapeutics
|
Feel Therapeutics is a digital precision medicine company delivering objective data and passive measurement for mental health. The company develops physiological and digital biomarkers and therapeutics for mental health. Its Feel data monitoring device leverages five embedded sensors via the wristband. Feel collects biometric data and analyzes themusing the latest cutting-edge methods of computer science to develop digital biomarkers.Feel Therapeutics, formerly known as Sentio Solutions. | $830K / Convertible Note / Apr 10, 2024 | |
Motif Neurotech
|
Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $18.8M / Series A / Jan 24, 2024 | |
TARA Mind
|
Tara Mind provides safe and equitable access to psychedelic-assisted therapy in order to prevent mental health crises. | $8M / Seed / Jan 23, 2024 | |
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Satori Capital invest in?
Satori Capital invests primarily in Health Care, Medical and E-Commerce startups, most often at Series A and Seed stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Satori Capital?
Public channels for Satori Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Satori Capital?
The team at Satori Capital includes Christiana Wyly (Operating Partner), Chad Cook (Director - Business Development) and Claire McInnis (Vice President of Finance), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
